Skip to content

What’s Happening in the Month Ahead: December 2017

What’s Happening in the Month Ahead: December 2017

Can Conference Save Orphan Drug Tax Credit?

Orphan drug developers will be watching closely in the next few days as the GOP’s tax reform package goes to conference committee. Congress has to reconcile differences between the Senate version, which cuts the orphan drug tax credit from 50% to 27.5%, and the House bill, which eliminates it completely. The Foundation Fighting Blindness (FFB) has joined with 90 other organizations in opposing the cuts.

Santen Has PDUFA Date for Uveitis Indication

The Food and Drug Administration this month could deliver a big present to Santen Pharmaceutical Co. on December 24 – which is a Sunday – the date the FDA set to complete its review of Santen’s new drug application (NDA) for intravitreal sirolimus for treatment of noninfectious posterior segment uveitis, per the Prescription Drug User Fee Act (PDUFA). The FDA could act before the year runs out. The agency accepted the NDA for the indication back in April.

HHS Nominee, Ophthalmologist’s Son,
May Get a Hearing

The Senate Finance Committee may hold a hearing this month on the nomination of Alex Azar II to replace Tom Price as secretary of Health and Human Services (HHS). Azar has a connection to ophthalmology: His father, an MD also named Alex Azar, is a retired ophthalmologist and founder of the Azar Eye Institute in Maryland, as well as a former instructor at Johns Hopkins University. Azar the younger, a lawyer, was president of Eli Lilly’s US affiliate before starting his own consulting firm, and was deputy HHS secretary under George W. Bush.

Mallinckrodt to Present at BMO Conference

Specialty pharma company Mallinckrodt Pharmaceuticals will present at the BMO Prescriptions for Success Healthcare Conference, December 14, at the Westin Grand Central New York. Executive VP and CFO Matthew Harbaugh and executive VP and CSO Steven Romano, MD, will represent the company in a fireside chat at 8 a.m. Eastern time.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

Eyeing Gene Therapy’s Ocular Future

Eyeing Gene Therapy’s Ocular Future

OIS Index Deep in Bear Territory in Q3

OIS Index Deep in Bear Territory in Q3

Retina Treatment Beyond Protocol

Retina Treatment Beyond Protocol

What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

Innovation Case Study: LensGen Focusing on a Complete Presbyopia Correcting IOL for Declining Vision

Innovation Case Study: LensGen Focusing on a Complete Presbyopia Correcting IOL for Declining Vision

5 Factors for Evaluating Investments in the Retina Space

5 Factors for Evaluating Investments in the Retina Space

About The Author

Rich Kirkner

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.
Scroll To Top